Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGN101
- Development stage
- Discontinued
- Lead developer
- Symphogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
IGN101 is an active cancer vaccine composed of the murine monoclonal antibody edrecolomab (17-1A) adsorbed onto aluminum hydroxide. It targets the Epithelial Cell Adhesion Molecule (EpCAM), a protein highly expressed in approximately 70% of epithelial cancers, including colorectal, rectal, and lung tumors. The vaccine is designed to stimulate the patient's immune system to produce an anti-idiotypic antibody response (Ab2) and a subsequent anti-anti-idiotypic response (Ab3) that recognizes and attacks EpCAM-expressing tumor cells. Developed by Igeneon (a subsidiary of Aphton), IGN101 was evaluated in several clinical trials for epithelial malignancies. However, a large Phase II/III trial in patients with non-small cell lung cancer (NSCLC) failed to demonstrate a survival benefit, leading to the cessation of its development for that indication.
- Other names
- edrecolomabMab17-1AMab-17-1AMab 17-1A17-1A
02
Targets
EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on IGN101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGN101.